arrow_back Back Filing freshness 20-F FY 2025 SEC EDGAR

download Export Data

Baird Medical Investment Holdings Ltd

BDMD

$1.24 ▲ +0.08 (+6.90%) at close

4 Visible periods

30 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Baird Medical Investment Holdings Ltd faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $34.5M

Dividend Yield —

Revenue Growth -39.2% ↘

Op. Margin -113.7% ↘

ROIC -66.8% ↘

FCF / Share $-0.05 ↗

Trailing P/E —

Price / Book 1.2x

FCF Yield —

Debt / Equity 0.28

info Valuation on last close. End-of-day price, Aug 7, 2026.

4-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$22.54M

↓ -39.2% —

Net Income Profit after all expenses

$-27.28M

↓ -319.0% —

Operating Margin Operating profit as % of sales

-113.7%

↓ -375.0% 2th

FCF / Share Free cash flow per share

$-0.05

↑ +88.1% —

Long-Term Debt Long-term obligations

$8.72M

↑ +153.4% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Operating Margin (%)Operating Margin (%) is in the bottom quartile
Profit Margin (%)Profit Margin (%) is in the bottom quartile
Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↑

Returns

Financial Health ↑

Cash Quality

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 5 metrics

Metric	FY 2025 Dec 31, 2025 20-F ↗	FY 2024 Dec 31, 2024 20-F ↗	FY 2023 Dec 31, 2023 20-F ↗	FY 2022 Dec 31, 2022 20-F ↗
Revenue Growth YoY (%)	-39.2% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-589%)	17.7% Good Good Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+122%)	-10.4% Weak Weak Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-229%)	—
EPS Growth YoY (%)	N/M	39.0% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	-16.3% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—
Net Income Growth YoY (%)	N/M	16.8% Good Good Year-over-year change in net income	-16.6% Weak Weak Year-over-year change in net income	—
FCF Growth YoY (%)	88.1% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	-193.4% Weak Weak Year-over-year change in free cash flow	32.5% Excellent Excellent Year-over-year change in free cash flow	—
Revenue CAGR 3Y (%)	-13.7% Weak Weak Compound annual revenue growth over 3 years	—	—	—

💰 Are margins durable? 5 metrics

Metric	FY 2025 Dec 31, 2025 20-F ↗	FY 2024 Dec 31, 2024 20-F ↗	FY 2023 Dec 31, 2023 20-F ↗	FY 2022 Dec 31, 2022 20-F ↗
Operating Margin (%) (%)	-113.7% Weak ↓ Weak Declining Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-858%)	41.4% Excellent ↑ Excellent Improving Operating income as a percentage of revenue Optimal: > 15% vs Sector: Above avg (+176%)	37.7% Excellent Excellent Operating income as a percentage of revenue Optimal: > 15% vs Sector: Above avg (+151%)	38.8% Excellent Excellent Operating income as a percentage of revenue Optimal: > 15% vs Sector: Above avg (+159%)
Effective Tax Rate (%) (%)	-4.4% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	10.6% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	13.8% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	12.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%
Profit Margin (%) (%)	-121.0% Weak ↓ Weak Declining Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1109%)	33.6% Excellent → Excellent Stable Net income as a percentage of revenue Optimal: > 15% vs Sector: Above avg (+180%)	33.9% Excellent Excellent Net income as a percentage of revenue Optimal: > 15% vs Sector: Above avg (+182%)	36.4% Excellent Excellent Net income as a percentage of revenue Optimal: > 15% vs Sector: Above avg (+203%)
FCF Margin (%) (%)	-6.2% Weak ↑ Weak Improving Free cash flow as a percentage of revenue Optimal: > 10%	-24.8% Weak ↓ Weak Declining Free cash flow as a percentage of revenue Optimal: > 10%	-11.6% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	-15.5% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%
FCF / Net Income (x)	0.05x Weak ↑ Weak Improving Free cash flow relative to reported net income Optimal: > 1x	-0.74x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	-0.34x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	-0.42x Weak Weak Free cash flow relative to reported net income Optimal: > 1x

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 20-F ↗	FY 2024 Dec 31, 2024 20-F ↗	FY 2023 Dec 31, 2023 20-F ↗	FY 2022 Dec 31, 2022 20-F ↗
Return on Invested Capital (%)	-66.8% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	31.8% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	27.4% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-36.8% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	19.6% Excellent Excellent Operating profit relative to total assets Optimal: > 10%	20.9% Excellent Excellent Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	-87.0% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-680%)	31.4% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+109%)	29.8% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+99%)	—

⚖️ Is the balance sheet risky? 4 metrics

Metric	FY 2025 Dec 31, 2025 20-F ↗	FY 2024 Dec 31, 2024 20-F ↗	FY 2023 Dec 31, 2023 20-F ↗	FY 2022 Dec 31, 2022 20-F ↗
Debt to Equity (x)	0.28x Excellent ↑ Excellent Improving Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-54%)	0.09x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-86%)	0.05x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-92%)	—
Interest Coverage (x)	-72.33x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	39.41x Excellent ↓ Excellent Declining Operating income divided by interest expense Optimal: > 5x	52.04x Excellent Excellent Operating income divided by interest expense Optimal: > 5x	55.90x Excellent Excellent Operating income divided by interest expense Optimal: > 5x
Net Debt (USD)	$8.54M	$472.33K	$1.61M	—
Debt / EBITDA (x)	-0.36x Excellent ↓ Excellent Declining Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	0.21x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	0.13x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	—

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 20-F ↗	FY 2024 Dec 31, 2024 20-F ↗	FY 2023 Dec 31, 2023 20-F ↗	FY 2022 Dec 31, 2022 20-F ↗
Revenue per Share (USD)	$0.81	$1.70	$1.23	$1.37
Basic EPS, GAAP (USD)	$-0.98	$0.57	$0.41	$0.49
Free Cash Flow per Share (USD)	$-0.05	$-0.42	$-0.14	$-0.21
Book Value per Share (USD)	$1.02	$1.35	$1.22	—
Tangible Book Value per Share (USD)	$1.02	$1.35	$1.21	—
Basic Weighted Avg Shares (shares)	27.79M	21.83M	25.56M	25.56M

🏦 How resilient is the balance sheet? 3 metrics

Metric	FY 2025 Dec 31, 2025 20-F ↗	FY 2024 Dec 31, 2024 20-F ↗	FY 2023 Dec 31, 2023 20-F ↗	FY 2022 Dec 31, 2022 20-F ↗
Working Capital (USD)	$22.61M	$26.79M	$21.11M	—
LT Debt (USD)	$8.72M	$3.44M	$1.61M	—
Total Equity (USD)	$31.37M	$39.66M	$35.75M	—

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 20-F ↗	FY 2024 Dec 31, 2024 20-F ↗	FY 2023 Dec 31, 2023 20-F ↗	FY 2022 Dec 31, 2022 20-F ↗
Sales/Revenue/Turnover (USD)	$22.54M	$37.04M	$31.46M	$35.09M
Depreciation Expense (USD)	$1.10M	$1.13M	$991.75K	$862.57K
Net Income, GAAP (USD)	$-27.28M	$12.45M	$10.66M	$12.77M
Operating Cash Flow (USD)	$-1.34M	$-6.31M	$-1.02M	$485.97K

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 4 years · 3 quarters

Baird Medical Investment Holdings Ltd

Analytical Summary

4-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare BDMD with peers